Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Completed · Not applicable

Conditions studied: HIV Infections

In brief

This study examines the long-term effects of interleukin-2 (IL-2) in combination with anti-HIV drugs, or highly active antiretroviral therapy (HAART). The purpose of this study is to see if IL-2 can increase the number of CD4 cells (cells of the immune system which fight infection) in HIV-infected patients who have completed ACTG 328. HAART is often successful in decreasing viral load (level of HIV in the blood), but these drugs have not been able to restore the immune systems of HIV-infected patients. IL-2 is a substance naturally produced by the body's immune cells. In ACTG 328, IL-2 is tested to see if it can increase the number of CD4 cells and "boost" a patient's immune system. This study is a follow-up to ACTG 328 so that patients who are benefiting from IL-2 can continue to take it and patients in the control group who do not receive IL-2 can start taking it.

Key facts

Study ID: NCT00000923
Run by: National Institute of Allergy and Infectious Diseases (NIAID)
People needed: 110
Expected to finish: 2004-08-01
Last updated by the study team: 2012-05-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients may be eligible for this study if they:
Are HIV-positive.
Have completed at least 84 weeks of treatment on ACTG 328.
Have had a 25 percent or greater increase in CD4 cell count above the ACTG 328 Week 11 value (only applies to patients who received IL-2 during ACTG 328).
Are 18 years of age or older.
Agree to practice abstinence or use a barrier method of birth control (such as condoms) during the study. (This study has been changed. Hormonal methods of birth control such as birth control pills are no longer allowed.)

You may not qualify if…

Patients will not be eligible for this study if they:
Have significant heart disease or are taking certain heart medications. Patients with hypertension who are being treated are eligible.
Have taken certain medications that might affect the immune system within 4 weeks of study entry including corticosteroids, interferons, or thalidomide.
Have taken rifampin, rifabutin, or St. John's wort within 7 days of study entry. (This study has been changed. St. John's wort was not in the original version.)
Are taking certain investigational anti-HIV drugs.
Are taking indinavir and any of the following within 2 weeks of study entry: cisapride, terfenadine, astemizole, midazolam, triazolam, ketoconazole, itraconazole, or delavirdine.
Have cancer requiring chemotherapy. Local radiation therapy is allowed.
Have untreated thyroid disease.
Are allergic to albumin.
Have a serious mental illness.
Have a history of an autoimmune disease, including inflammatory bowel disease and psoriasis.
Have a central nervous system disease or seizures, if these have been active within 1 year prior to study entry.
Abuse drugs or alcohol.
Are pregnant or breast-feeding.

Where it is running

Alabama Therapeutics CRS — Birmingham, Alabama, United States
USC CRS — Los Angeles, California, United States
Harbor-UCLA Med. Ctr. CRS — Torrance, California, United States
Univ. of Hawaii at Manoa, Leahi Hosp. — Honolulu, Hawaii, United States
Univ. of Iowa Healthcare, Div. of Infectious Diseases — Iowa City, Iowa, United States
Tulane Univ. A1701 CRS — New Orleans, Louisiana, United States
St. Louis ConnectCare, Infectious Diseases Clinic — St Louis, Missouri, United States
Washington U CRS — St Louis, Missouri, United States
Mt. Sinai Med. Ctr. A0404 CRS — New York, New York, United States
Case CRS — Cleveland, Ohio, United States
The Ohio State Univ. AIDS CRS — Columbus, Ohio, United States
University of Washington AIDS CRS — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.